Glycofi, Incorporated

Merck Sharp + Dohme Corp.

Dartmouth College

W James Cook

Piotr Bobrowicz

Warren Charles Kett

Charles L Sentman

Byung-Kwon Choi

David Graber

The present disclosure generally relates to novel chimeric antigen receptors ('CARs'), modified regulatory T cells (“Tregs”) expressing such CARs and/or Tregs which are engineered to express neurodegenerative disease modifying molecules, e.g., which express molecules which prevent oxidative/inflammatory activity, or which promote neuronal growth/survival such as nerve growth factors or non-classical neurotrophic factors. The present disclosure also generally relates to compositions containing such modified Tregs, and methods of use thereof as therapeutics, in particular for treating and preventing neurodegenerative diseases and symptoms associated with therewith, and/or for slowing the onset of such neurodegenerative diseases, particularly in persons at risk because of genetic factors or in persons exhibiting early signs of developing such a neurodegenerative disease.

Chimeric antigen receptors for treatment of neurodegenerative diseases and disorders

A method is described for producing protein compositions having reduced amounts of O-linked glycosylation. The method includes producing the protein in cells cultured in the presence of an inhibitor of Pmt-mediated O-linked glycosylation and/or in the presence of one or more &#x3b1;-1,2-mannosidases.

Production of glycoproteins with reduced O-glycosylation

Growing community of inventors

Hanover, NH, United States of America

W James Cook